Kent Lake Comments on Quanterix’s Value Destructive Bridge Financing for Financially Troubled Akoya

In This Article:

Disturbed that Quanterix Is Apparently Moving Forward with One of the Most Shareholder Unfriendly Aspects of Merger Agreement with Akoya

Encourages Shareholders to Vote AGAINST Both Proposals Related to Approval of the Transaction

RINCON, Puerto Rico, April 07, 2025--(BUSINESS WIRE)--Kent Lake PR LLC ("Kent Lake") is a holder of approximately 7.5% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX). Today, Kent Lake issued a statement related to recent disclosures indicating that Quanterix has officially entered into a Securities Purchase Agreement under which Akoya Biosciences ("Akoya") (NASDAQ: AKYA) has the ability to sell the Company up to $30 million in convertible notes.

Kent Lake has previously issued a public presentation detailing its opposition to the Company’s proposed transaction (the "Transaction") with Akoya and has also nominated three highly qualified, independent candidates for election to the Quanterix Board of Directors (the "Board").

Kent Lake’s statement follows:

"We are deeply disturbed that Quanterix is moving forward with one of the most egregious elements of the merger agreement with Akoya (the "Merger Agreement"). Quanterix is now poised to provide $30 million in bridge financing to Akoya before shareholders have even had the opportunity to vote on the Transaction. What’s worse is the fact that Akoya can draw on these notes until July 9, 2025, even if the Transaction is lawfully terminated before that date.

As a result, Quanterix is now shoring up Akoya, which faces a near-term liquidity crisis, with $30 million of shareholders’ money. This sort of backdoor financing is highly unfavorable to Quanterix shareholders, who will now be left holding Akoya’s high-risk subordinated distressed debt. We believe the Board has further violated its fiduciary duties by not providing comprehensive disclosures on the bridge financing. Furthermore, Quanterix shareholders have not been provided with any disclosure around the commercial reasonableness of the bridge financing terms – for which apparently no fairness opinion was issued.

More broadly, we call on Quanterix to provide further disclosure about how Akoya’s desperate need for a bridge loan factored into the Board’s valuation of Akoya and, if Akoya truly needs such a loan, whether that calls into question the forecasts used by Quanterix to justify the Transaction.

This latest development is yet another unfortunate illustration of how the Transaction is not in the best interests of Quanterix shareholders and why they should vote AGAINST both proposals related to its approval."